

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

42/Primer Cat
SNT
1-09-01
PATENT
P239US00

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Thomas NILSSON
Appl. No.: 09/664,385
Filed: September 18, 2000
For: METERED ELECTRO-DOSE

Group: 3721
Examiner: UNASSIGNED

LETTER

Assistant Commissioner for Patents
Washington, DC 20231

Date: November 30, 2000

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):

<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
SWEDEN	0003082-5	August 3, 2000


A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By


Robert J. Patch, #17,355

RJP:mdp
P239US00


745 South 23rd Street, Suite 200
Arlington, Virginia 22202
(703) 521-2297

Attachment

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg
Certificate



Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande Microdrug AG, Hergiswil NW CH
Applicant (s)

(21) Patentansökningsnummer 0003082-5
Patent application number

(86) Ingivningsdatum 2000-08-31
Date of filing

Stockholm, 2000-11-09

För Patent- och registreringsverket
For the Patent- and Registration Office


Therese Friberger

Avgift
Fee 170.-

RECEIVED
DEC -4 2000
TECHNOLOGY CENTER 3700

2000 -08- 3 1

Metered electro-dose

Huvudfaxen Kassan

TECHNICAL FIELD

The present invention relates to electrostatic dosing and more particularly to an electro-dose using electro-powder as well as a process and a method for
5 preparation of a metered electro-dose for inhalation into the deep or upper lungs by means of an inhaler device.

BACKGROUND

The dosing of drugs is carried out in a number of different ways in the
10 medical service today. Within health care more and more is focused on the possibility of dosing medical drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and patient-friendly administration of such substances.

15 A dry powder inhaler, DPI, represents a device intended for administration of powder into the deep or upper lung airways by oral inhalation. With deep lung should be understood the peripheral lung and alveoli, where direct transport of active substance to the blood can take place. Particle sizes, to reach into the deep lung, should be in a range 0.5 - 3 μm and for a local lung
20 delivery in the range 3 - 5 μm . A larger grain size will easily stick in the mouth and throat, and a smaller grain size may accompany the expiration air out again.

25 To succeed with systemic delivery of medical powders to the deep lung by inhalation there are some criteria, which have to be fulfilled. The most important is a very high degree of de-agglomeration of the medical powder but also an exact dose is of great importance. This is not possible with dry powder inhalers of today without special arrangements as for example a so called spacer.

30 By means of a spacer the small grains are evenly distributed in a container from which the inhalation can take place. Upon inhalation from the spacer the fine powder floating free in the air will effectively reach the alveoli of the

lung. This method in principle has two drawbacks, firstly difficulties to control the amount of medicine emitted to the lung as an uncontrolled amount of powder sticks to the walls of the spacer and secondly difficulties in handling the relatively space demanding apparatus.

5

Powders for inhalers have a tendency of agglomerating, in other word to clod or to form small or larger lumps, which then have to be de-agglomerated. De-agglomeration is defined as breaking up agglomerated powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-

10 agglomeration is performed as a stage one during dosing and as a final stage two during the patient's inspiration through the DPI.

15

Inhaler devices normally use the force exerted by the patient's more or less normal inspiration effort for de-agglomerating the medical substance administered when inhaling in an effort to bring as much as possible of the active substance into the lungs. This often leads to inhaler designs using high pressure drops, which will put the patient's lungpower to the test.

20

One major problem with some of the technique described above is to also obtain a low relative standard deviation (RSD) between doses with this type of technique due to lack of in line control possibilities in production making it hard to be in compliance with regulatory demands.

25

As already noted for an optimum amount of substance to reach the alveoli, an administered powder dose should preferably have a grain size between 0.5 and 3 μm . Besides, the inspiration must take place in a calm way to decrease air speed and thereby reduce deposition in the upper respiratory tracts.

30

Technologies to de-agglomerate today include advanced mechanical and aerodynamic systems and combinations between electrical and mechanical filling systems that can be seen in for instance in U.S. Patent No. 5,826,633. Further there are systems disclosed for dispersing aerosolized doses of

medicaments, e.g. U.S. Patent No. 5,775,320, U.S. Patent No. 5,785,049, and U.S. Patent No. 5,740,794. Furthermore, in our International Publications WO 00/0636 and WO 00/6235 principles for de-agglomeration and classification are disclosed.

5

The term electro-powder refers to a micronized medical powder presenting controlled electrostatic properties to be suitable for electrostatic administration in an inhaler device. Such an electro-powder provides possibilities for a better dosing from electrostatically operating equipment
10 such as disclosed in our U.S. Patent No. 6,089,227 as well as our Swedish Patents No. 9802648-7 and 9802649-5, which present excellent inhalation dosing performance.

The state of the art also discloses a number of solutions for depositing
15 powder for dosing. U.S. Patent No. 6,063,194 discloses a powder deposition apparatus for depositing grains on a substrate using an electrostatic chuck having one or more collection zones and using an optical detection for quantifying the amount of grains deposited. U.S. Patent No. 5,714,007 and U.S. patent No. 6,007,630 disclose an apparatuses for electrostatically
20 depositing a medicament powder upon predefined regions of a substrate, the substrates being used to fabricate suppositories, inhalants, tablet capsules and the like. In U.S. Patent No. 5,699,649 and U.S. Patent No. 5,960,609 are presented metering and packaging methods and devices for pharmaceuticals and drugs, the methods using electrostatic phototechnology to package
25 microgram quantities of fine powders in discrete capsule and tablet form.

Devices of prior art technology does often not reach a sufficiently high degree of de-agglomeration and an exact dose is not well developed and leaves much to be desired when it comes to dosage conformity and lung deposition effectiveness of the medical substance. Therefore, there is still a demand of
30 pre-fabricated high accuracy pre-metered doses to be loaded into an inhaler device, which then will ensure repeated exact doses to be given. The active dry powder then must possess a fine particle fraction, which guarantees its

administration to a position within the lung of a patient where it will exert its expected effect.

SUMMARY

5 An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a pre-metered medical powder intended for use in a dry powder inhaler and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being onto a device member forming a dose carrier. The electro-
10 dose prepared from an electro-powder presenting a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5-5 μm . The electro-powder of such a pre-metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 $\mu\text{C/g}$ and presents a charge
15 decay rate constant Q_{50} of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity a_w of less than 0.5.

The electro-dose porosity is adjusted by means of a mechanical and/or electrical vibration of the dose receiving device member during the electro-
20 dose build-up operation to obtain an optimized porosity value of 75 to 99.9% calculated as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$. A number of parameters must be kept under strict control during the processing in order to obtain the desired electro-dose for utilization in a dry powder inhaler.

25 An electro-dose according to the present invention is set forth by the independent claim 1 and the dependent claims 2 to 7. Furthermore a method for obtaining an electro-dose is set forth by the independent claim 8 and further embodiments of the method are set forth by the dependent claims 9 to 21. Also a process for the manufacturing of an electro-powder is
30 set forth by the independent claim 22 and the dependent claims 23 to 31.

SHORT DESCRIPTION OF THE DRAWINGS

The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken together with the accompanying drawings, in which:

- FIG. 1 is a simplified flow chart for creating an electro-dose from an electro-powder;
- 10 FIG. 2 is a flow chart illustrating the powder dose analysis when preparing the electro-dose;
- FIG. 3 is a summary flow chart illustrating preparation of the electro-dose;
- 15 FIG. 4 illustrates a cross section of a dose carrier provided with a conducting or dissipative sheet for the preparation of an electro-dose by electrostatic methods;
- 20 FIG. 5 illustrates a cross section of a dose carrier made from a conductive or dissipative material for the preparation of an electro-dose by electrostatic methods;
- FIG. 6 illustrates a cross section of a dose carrier containing a buried conductive material sheet inside an isolative material for the preparation of an electro-dose by means of electrostatic methods;
- 25 FIG. 7 illustrates a cross section of a dose carrier containing several separate buried conductive material sheets for the preparation of an electro-dose by electrostatic methods;
- 30 FIG. 8 illustrates transfer of electro-powder to a carrier by means of an electrostatic field;

FIG. 9 illustrates transfer of electro-powder to the carrier by means of an electrostatic field and a focussing means;

5 FIG. 10 illustrates a control circuitry utilized in the transfer of powder according to FIG. 9;

FIG. 11 illustrates an applied alternating electric field as function of time in transferring powder particles to the carrier;

10

FIG. 12 illustrates displacement of carrier surface in micrometers as a function of time;

FIG. 13 illustrates a "tree" structure in an enlarged view initial positioning of de-agglomerated particles at the carrier surface;

15

FIG. 14 illustrates a "sponge" structure in an enlarged view of particles positioned at the carrier surface after a compaction operation;

20 FIG. 15 illustrates in an enlarged view of a "velvet" structure of the particles at the carrier surface;

FIG. 16 is graph representing dose porosity and de-agglomeration for particles of sizes 3 and 5 micrometers;

25

FIG. 17 is a graph representing calculation of de-agglomeration for particles up to 3 micrometers from an initial electro-powder particle size;

30

FIG. 18 is a graph representing calculation of de-agglomeration for particles up to 5 micrometers from an initial electro-powder particle size; and

FIG. 19 shows a measurement set-up used for a measurement of size distribution and mass and further calculation of deagglomeration and flow rate.

DESCRIPTION

In a starting step 100 of Figure 1 an electrostatically dosed electro-powder is brought into a powder dose analysis step 110. Dosing parameters are then determined in a step 120 to finally result in an electro-dose in a step 160. Electro-powder here is defined as a prepared active substance meeting a set of electrical specifications for optimum electrostatic dosing properties. Specific charge is expressed in Coulomb per mass unit in this context as $\mu\text{C/g}$ after charging. Such an electro-powder should present an absolute specific charge, after charging by induction, corona, or tribo-charging, of the order of 0.1 to 25 $\mu\text{C/g}$ (0.1×10^{-6} – 25×10^{-6} Coulomb/gram of negative or positive charge) and a discharge rate constant $Q_{50} > 0.1$ sec. Q_{50} is defined as the time until 50% of the electrostatic charge is discharged, (for instance after a corona charging in an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD). Furthermore the electro-powder should constitute a powder with more than 50 % of fine particle fraction with a particle size less than 5 μm and have a water content of less than 4 % together with a water activity $a_w < 0.5$, preferably being between 0.2 and 0.3 and a tap density of less than 0.8 g/ml.

Water content is defined as the amount of weakly bound water. It's calculated as the difference between the total water content, determined e.g. by Karl-Fischer titration, and the amount of strongly bound water, e.g. crystal water, characteristic for the substance. Water activity a_w is a dimensionless quantity, which may, for instance, be measured with an AquaLab model series 3 TE. Tap density is, for instance, measured by using a Dual Autotap from Quantachrome[®] Corporation according to British Pharmacopoeia for Apparent Volume method. Both water activity and tap density are quantities well known to a person skilled in the field of chemistry analysis.

2000-08-31

8

Huvudfaxen Kassar

All measurements are performed at room temperature defined as in a range of 18 - 25°C in air or nitrogen atmosphere with a relative humidity less than 5 %. The absolute specific charge is the charge the electro-powder presents after an electrostatic charging being performed and subsequently measured
5 in $\mu\text{C/g}$ with an electrometer, e.g. a Keithley Electrometer 6512 or an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD.

The electro-dose is then defined as an electrostatically dosed electro-powder possessing the following specification: Porosity defined as $Dp_{\text{electro-dose}} = 100 - 100(\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}}) > 75\%$ and having a optimized de-agglomeration of $> 25\%$ and more preferable being more than 50 % and most preferable more than 75 % and meeting a dosage uniformity according to USP 24-NF 19 Supplement 601 Aerosols/Physical Tests pages 2674 - 2688, which will hereafter be referred to as USP, and also possessing a de-
15 agglomeration difference measured according to USP compared with the de-agglomeration at a flow representing a pressure drop over the inhaler device reduced to 1 kPa $(1 - (\text{de-agglomeration}(Q_{1\text{kPa}}) / \text{de-agglomeration}(Q)) \times 100) < 25\%$ and more preferably less than 10 % and most preferably less than 5 %.

20 Particles intended for the deep lung, here defined as the peripheral lung and alveoli, where direct transport of an active substance to the blood can take place, should have a particle size in the range 0.5 - 3 μm . For treatment in the local lung, defined as upper parts of the lung, where treatment normally takes place for instance in asthma treatment, the particle size should be in
25 the range 3-5 μm . All particle sizes are defined as the size of the particles measured with for instance a laser diffraction instrument e.g. a Malvern Mastersizer for physical size classification or an Andersen Impactor for an aerodynamic size classification and if not stated otherwise always referred to as aerodynamic particle size.

30 The active substance is a pharmaceutical active chemical or biological substance intended for administration into the deep or upper lung airways by oral inhalation from a dry powder inhaler device (DPI), where inhaled

Huvudfoxen Kasson

macromolecules could be from the following therapeutic areas: Insulin rapid intermediate and slow acting and diabetes peptides, interferons, interleukins and antagonists, antibodies, peptides for immune suppression, nerve growth factors, vaccines, gene therapies, genetically modified virons and/or

5 bacterias, parathyroid hormone, osteoporosis peptides, antiobesity peptides, luteinizing hormone releasing hormone (LHRH) and LHRH analogs, somatostatin analogs, human calcitonin, colony stimulating factor, erythropoietins, growth hormones, erectile dysfunction, anti-pregnancy hormones.

10

The active substance also could be selected from the pharmaceutical active chemical and biological substances vasopressin, a vasopressin analogue, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone,

15 growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, a somatostatin analogue, a gonadotropin agonist analogue, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, prolactin, an interleukin, a growth factor, a polypeptide vaccine, an enzyme, an endorphin, a glycoprotein, a lipoprotein kinas, intra-cellular

20 receptors, transcription factors, gene transcription activators/repressors, neurotransmitters (natural or synthetic), proteoglycans., a polypeptide involved in the blood coagulation cascade, that exerts its pharmacological effect systemically or any other polypeptide that has a molecular weight (Daltons) of up to 50 kDa or from the group consisting of proteins,

25 polysaccharides, lipids, nucleic acids and combinations thereof or from the group consisting of leuprolide and albuterol or is among opiates or nicotine and nicotine derivates or scopolamin, morphine, apomorphine analoges or equivalent active substances or pharmaceutical active chemicals for asthma treatment, e.g. budesonid, salbutamol, terbutalinsulphate, salmeterol,

30 flutikason, formoterol or salts thereof.

The first step 110 of the powder dose analysis includes a series of at least five powder doses to be analyzed in a step 210 illustrated in Figure 2.

Standard settings of the input parameters are then used, which are well spread over an interval to have a possibility to in a sequence of steps **220** to **270** determine the most important specifications regarding height, area, mass, porosity and dose de-agglomeration at flow rate Q according to USP and Q_{1kPa} . Very important is to determine if a porosity adjustment is necessary to be performed by active use of mechanical and/or electrical methods in the preparation of the electro-powder into an electro-dose by adjusting the dose porosity to an optimum giving an optimum inhalation performance regarding de-agglomeration. The porosity of the electro-dose is then defined as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ producing a measure in percent.

Dose height is then measured in step **220** for the powder doses of step **210** using for instance a Laser displacement sensor from Keyence LK-031 with electronics LK-2001 and cables LK-C2 giving the height of the powder bed in μm .

The electro-powder doses tested in step **210** are then brought to step **230** for dose area investigation, wherein the projected size of the powder dose onto the device member is measured with, e.g., a stereo microscope from Olympus and noted down in millimeters with a resolution of $100 \mu\text{m}$.

A machine script is a program to control a sequence of operations inside a feeding device **45** in Figure 8, which is a device that in a controlled way is feeding electrostatically charged electro-powder into an electrical field allowing selected electro-powder particles with the right particle size to be transported to the device member and having a set of parameters added to the script to control the flexible settings of a powder dose. This electrostatic dosing device **45** is also performing a control of the absolute specific charge and all other essential parameters, e.g. feeding rate of de-agglomerated electro-powder by the machine script. The dose de-agglomeration step **240** is defined as breaking up agglomerated electro-powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is

performed as a stage one during dosing of the electro-powder and as a final stage two during the patient's inspiration of the electro-dose through the DPI. De-agglomeration is measured, e.g. using a Malvern Mastersizer as an example of a laser diffraction instrument used to measure particle size distribution both in aerosols and in liquids for physical size classification or an Andersen Impactor for an aerodynamic size classification as described in USP.

Table I

Dosing Time (s)	Vibration KHz; μm	Frequency $t_1; t_2; E_1; E_2$ s ; V	Electrical field E V/mm	Filter Potential V_f	Machine Script
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;300;-50	300	650	Test QC 1
8	0;0	0,5;0,01;350;-50	350	700	Test QC 1
8	0;0	0,5;0,01;400;-50	400	750	Test QC 1
8	0;0	0,5;0,01;500;-50	500	800	Test QC 1
8	0;0	0,5;0,01;1000;- 50	1000	1000	Test QC 1

10

The electro-powder de-agglomeration is performed in the electrostatic feeding device 45 where de-agglomeration and classifying of the electro-powder is performed then resulting in obtaining a majority of the powder particles being in the correct size range 0,5-5 μm for being dosed onto the device member. This de-agglomeration operation is referred to as de-agglomeration #1 or electro-powder de-agglomeration.

15

The electro-dose de-agglomeration or de-agglomeration #2 takes place when sucking off the electro-dose from the device member accompanied with a de-agglomeration of the dose in the mouthpiece.

20

Huvudfoxen Kossan

De-agglomeration #2 is measured as two different airflow values, whereby the first airflow Q is according to USP and the second airflow Q_{1kPa} is at a pressure drop over the inhaler device of 1 kPa. The two different airflow values are for determining if an increase in inhalation energy has a major effect on the de-agglomeration #2. It is important to minimize the effect of the inhalation energy by adjusting the de-agglomeration #2 and the dosing properties and de-agglomeration #1 to meet the electro-dose specification.

The electro-dose de-agglomeration is measured using a mouthpiece with a nozzle in the procedure which is identical to the construction and settings inside the DPI intended to be used and with a same device member as is to be used with the DPI. The portion at the end of the mouthpiece towards the device member has to be aerodynamically correctly constructed to minimize retention.

The de-agglomeration is then calculated using the electro-powder particle size specification as input material and the High Pressure Liquid Chromatography HPLC analysis regarding particle size distribution after a standard sucking off from the device member as the output result. The de-agglomeration of the electro-dose is then calculated as percent of de-agglomerated electro-dose at 3 μm , $DD_{3\mu m}$, and 5 μm , $DD_{5\mu m}$, compared to the amount of powder less than 3 μm and 5 μm in the original electro-powder. The de-agglomeration must be more than 25 % to meet the electro-dose specification. Fig 17 and fig 18 present calculations of de-agglomeration at 3 μm and 5 μm , respectively, in a graphical representation marking the areas under the particle size distribution curves for the initial and resulting distributions respectively. The curves plotted with dots representing initial electro-powder size distribution and the curves plotted with squares representing resulting electro-dose size distribution.

The dose mass in step 250 is possible to be measured in two different ways. First option is to use a Malvern Mastersizer, where the powder is collected on a filter after analysis through the instrument. The filter is then possible to

analyze either using a balance, e.g. a Mettler Toledo UMT5 Ultra Microbalance or by chemical analyzes, e.g. a HPLC SpectraSYSTEM with a UV 6000 detector or any other suitable detector. A second option and also most preferable is to determine the powder mass using an Andersen
5 Impactor and analyze both the aerodynamic particle size distribution and the total mass using for instance the HPLC SpectraSYSTEM with a UV 6000 detector in accordance with USP.

10 To meet the electro-dose specification the mass must conform to the uniformity of dose stipulated in the USP and more preferable be between 95 % < label claim < 105 % when this will be possible by a proper control regarding the electro-powder and the electrostatic dosing device together with the machine script.

15 Results from the above analysis: dose height in step 220, dose area in step 230, dose de-agglomeration in step 240 and dose mass in step 250 is noted down for calculations.

20 Dose density is calculated from dose mass in micrograms from step 250 divided by dose height in millimeters from step 220 and divided by dose area in mm² from step 230 and noted down as dose density in µg/mm³ in step 260. Dose porosity in step 265 is here defined in percent as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ with the electro-powder density in this example being 1,4 kg/dm³. Dose mass per dose area is calculated in
25 step 270 as dose mass in µg from step 250 divided by dose area from step 230 and noted as µg/mm². The results are then combined with the settings presented in Table I and are presented with the results in Table II below.

30 Thus, all analytical results are noted down together with input data in an analytical report as step 280 forming a decision material for the step 120 of Figure 1 determining dosing parameters. The result of this example illustrates that, in order to obtain a high quality dose with respect to de-

2000-08-31

14

Huvudfaxen Kassar

agglomeration in step **240**, the dose porosity obtained at step **265** should be to approximately 98 % .

Table II

Test	Dose height 220 μm	Dose area 230 mm^2	Dose de-aggl. 240		Dose mass 250 μg	Dose density 260 $\mu\text{g}/\text{mm}^3$	Dose Porosity 265 %	Dose mass/area 270 $\mu\text{g}/\text{mm}^2$
			3 μm %	5 μm %				
1	196	40	80	82	77	9	99,4	1,9
2	92	40	81	84	73	20	98,6	1,8
3	76	40	81	85	75	25	98,2	1,9
4	64	40	84	87	78	30	97,9	2,0
5	69	40	83	89	77	28	98,0	1,9
6	124	40	77	84	173	35	97,5	4,3
7	137	40	74	81	214	39	97,2	5,4
8	148	40	66	73	365	62	95,6	9,1
9	135	40	63	68	415	77	94,5	10,4
10	124	40	58	64	520	105	92,5	13,0

5

The decision in step **120** determining dosing parameters is then used to make several powder dosing in a step **130** for tests and to verify that the chosen settings are correct and verified in a step **140** according to a repeated step of powder dose analysis. If the result of this powder dose analysis proves to be according to set specification for an electro-dose the settings is noted down for the continued manufacturing process.

10

On the other hand, if powder dosing according to step **130** results are not within set specification for an electro-dose, the result is in a step **145** returned to the step **120** of determining dosing and parameters for a new optimized parameter settings. The determining preparation of electro-dose as a step **310** in Figure 3 is then taking into account the specification of the electro-powder in step **300** and dosing parameters in step **320** to have a new set of tests for the preparation of the electro-dose. A very useful tool to optimize the electro-dose is to use a statistical planning method for the tests

15

20

to reduce the total amount of tests needed and fast finding the optimum preparation scheme for a desired electro-dose.

Figure 4 shows an illustrative cross section a device member with a
5 dissipative or conductive carrier area 14 as a dose receiver for the electro-
dose and an isolative material 10, e.g. plastic, having a surface resistance
greater than 10^{11} ohms.

Figure 5 illustrates a cross section with another material as walls where the
10 dissipative or conductive material 11 has a potential defined through an
applied voltage 12 and where a conductive material is a material with a
surface resistance $< 10^6$ ohms or a dissipative material with a surface
resistance between the conductive and the isolative material $10^6 <$
Dissipative material $< 10^{11}$ ohms.

15 Figure 6 shows in an illustrative cross section a device member with a
dissipative or conductive material area 24 located under or behind a thin
layer approximately 10-3000 μm of isolative material 10 and where the
dissipative or conductive material is having a set potential through an
20 applied voltage 12.

Figure 7 shows an illustrative cross section of a device member with two
separate dissipative or conductive materials 22 and 24 and a isolative
material 10, where the dissipative or conductive material 24 forms the dose
25 receiver of the electro-dose through a applied voltage 12 attracting the
electrostatically charged electro-powder and the conductive material 22 is a
conductive or dissipative material for applying a second electrical field to
guide the powder to the correct position through a second applied voltage
30 18.

In a further illustrative embodiment similar to Figure 5 the device member
material forming the dose carrier may be chosen from an isolative plastic
material, which is processed before dosing by ionized air to remove

electrostatic charges from its surface. In another embodiment an isolative plastic material is processed before dosing by introducing the device member into humid air to remove electrostatic charge from its surface. In a third embodiment the device member isolative plastic material is processed before dosing by combination of ionized air and humid air to remove electrostatic charges from its surface.

In still a further embodiment the device member is temporarily given a dissipative surface by applying a thin solvent layer onto its surface, e.g. water, carbon dioxide or other non-toxic and FDA approved solvent. Such a solvent layer is then applied with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing removing the solvent from the device member.

Figure 8 shows in an illustrative example a dosing and metering set-up where a feeding device 45 for electrostatically charged electro-powder is subject to an electrical field 48 created by a separate applied potential 46 measured in V/mm and intended for transporting the electrostatically charged powder in a controlled way for dosing, metering or measuring purposes. A total field acts between the device member and the electro-powder feeder 45 through two different adjusted potentials 12 and 46. Between the feeder 45 and the device member is situated a filter 44 to shield part of the device member not to be subject to dosing until the device member is in the correct position and then having a transportation of electrostatically charged electro-powder particles 49 metered onto the carrier portion of the device member.

Figure 9 shows an illustrative example a dosing and metering set-up with a device member 11 made from a dissipative material at which powder is dosed by an applied electrical field between the feeder of electrostatically charged electro-powder 45 and the device member utilizing an electrical filter 52 with a applied make-up potential to guide the powder to the correct position onto the carrier portion of the device member. The filter potential

also serves as a possibility to control depositing on and off in a simple way by switching the applied voltage to the filter between normal potential and a much lower potential compared to the potential applied to the device member in this example. The guiding of electrostatically charged electro-
5 powder particles 49 is then a function of applied voltage of the feeder of electrostatically charged electro-powder 49 and the voltage applied to the device member 12 and the potential of the filter 52. The filter 52 is supported by an isolative filter holding material 44.

10 Figure 10 shows in an illustrative example a dosing and metering set-up with a device member 11 in a dissipative material dosed onto by an applied electrical field between the feeder 45 of electrostatically charged electro-powder and the device member utilizing an electrical filter 52 with an applied make-up potential 59 to guide the powder to the correct position at
15 the carrier portion of the device member 11. The filter potential also serves as a possibility to control deposition on and off in a simple way by changing the potential of the filter 52. The guiding of electrostatically charged electro-powder particles 49 is then a function of applied voltage to the feeder 45 of electrostatically charged electro-powder and the applied voltage to the device
20 member 11 and the potential of the filter 52. The filter 52 is supported by an isolative filter holding material 44. The dose is possible to measure during the dosing and metering operation by using the electrometer 66 and switching the voltage 65 in front of a high voltage generator 67. During the dosing and metering operation it is also possible to control the density of the
25 electro-dose by utilizing a mechanical vibration 64 or an electrical frequency utilizing, e.g. the switching box 65 resulting in a possibility to control the electrical field and the mechanical movement according to Figures 11 and 12.

30 Figure 11 shows an example of electrical fields E_1 and E_2 applied as alternating fields at a pre-selected frequency to have the electro-powder to "dance" at the device member 11 to thereby achieve an optimum porosity for an optimum of de-agglomeration according to Figure 16. Figure 11 shows

how the total dosing time period T is divided up in periods t_1 when the electrical field is at a maximum value of E_1 and other time periods t_2 when the electrical field is at a minimum value of E_2 , whereby the time periods t_1 and t_2 are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds respectively.

5

Figure 12 illustrates an example of a set up with a mechanical vibration having a total dosing time period T and a maximum displacement of D_1 during t_1 and no displacement during the time period t_2 to make the dosed electro-powder particles to "dance" at the device member 11 and thereby, by means of a control of the applied field, having a controlled adjustment of the porosity to an optimum situation for an optimized de-agglomeration according to Figure 16, whereby the time periods t_1 and t_2 are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds, respectively.

10

Figure 13 shows a "tree" structure of powder particles at the device member 11 showing the ordering of particles of an electro-dose not being subject to adjustment of dose porosity disclosing chains of powder rising from the device member. The electro-powder particles 72 are forming "trees" of particles resulting in an extremely high porosity. The porosity of an electro-dose is calculated using the width and height of the "tree" structure together with the length to calculate the volume and then dividing the mass of the electro-dose with the volume to obtain the density of the electro-dose. The porosity is then calculated as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ in percent, where the density of the electro-powder in this example is 1.4 kg/dm³.

20

25

It should be noted that in the preferred process the carrier is turned with its receiving surface facing downwards as illustrated in Figures 13 to 15 when picking up the charged particles 72, 82 or 92. However, the process may also be performed as indicated by Figures 6 to 10.

30

Figure 14 shows an electro-dose on the device member 11 with a "sponge" structure defined as an intermediate structure of the electro-dose, where

2000-08-31

19

Huvudfoxen Kasson

some of the "tree" structures 82 have collapsed and are connected top to top forming a matrix with a medium to low density and less porosity through a adjusted density by electrical frequency or mechanical vibration during the dosing and metering operation thereby obtaining a lower porosity compared to the "tree" structure of Figure 13.

Figure 15 shows an electro-dose at a device member 11 presenting a velvet structure 92 after being porosity adjusted with the proper electrical frequency or mechanical vibration thereby obtaining a look like a smooth velvet cloth which shows much less porosity than the "sponge" structure.

Figure 16 illustrates the effect of a dose porosity adjustment in which the de-agglomeration of the electro-dose is measured at different porosities showing an optimum de-agglomeration both for particles less than 5 μm and for particles less than 3 μm having a porosity in the range marked as A also indicating that the electro-dose is independent of the flow at porosities inside the range A.

In the range marked B the de-agglomeration is in a transition area and showing medium flow dependence and a lower grade of de-agglomeration. In range C the porosity is lower and the powder much harder to de-agglomerate in dose de-agglomeration and also showing a strong dependence of the flow i.e. the energy level of the de-agglomeration #2 and are not suitable as an dose for inhalation and subject to optimization. $DD_{5\mu\text{m}}$ is the dose de-agglomeration at 5 μm and at a differential pressure according to USP and $DD_{1\text{kPa}}$ is also according to USP but at a pressure drop over the inhaler of 1kPa.

Measurement of de-agglomeration is performed, e.g., according to Figure 19, using an Andersen Impactor together with a mouthpiece and a device member in a set-up identical with the intended DPI for the electro-dose or instead of the Andersen Impactor using a Malvern Master Sizer S to measure the physical particle size. When the particle distribution is measured the de-

2000 -08- 3 1

20

Huvudfaxen Kassar

agglomeration can be calculated knowing the electro-powder particle size distribution.

The de-agglomeration is measured at two different rates of flow, flow-rate Q according to USP and at a flow-rate at 1 kPa pressure drop over the inhaler device according to USP. Measuring at two different flow-rates indicates if the electro-dose in the intended DPI is flow dependent or flow independent, as this may be an important aspect for the patient. If the difference in de-agglomeration is less than 25 %, when calculated as $(100 - 100 \times (\text{de-agglomeration}(Q_{1\text{kPa}}) / \text{de-agglomeration}(Q)))$, then the electro-dose meets the specifications, if the result is outside the electro-dose specifications further optimization of the electro-dose has to be performed by going back to step 310.

Figure 17 describes how the de-agglomeration at 3 μm is calculated using the initially input electro-powder under 3 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area with the calculated value of the surface of the first area and multiplying by a factor 100 the de-agglomerated amount below 3 μm is obtained in percent.

Figure 18 describes how the de-agglomeration at 5 μm is calculated using the initially input electro-powder under 5 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area in Figure 18 with the calculated value of the surface of the first area in Figure 18 and multiplying by a factor 100 the de-agglomerated amount below 5 μm is obtained in percent.

Figure 19 illustrates an example of a de-agglomeration and mass measurement set-up **71** identical to the inhaler to be used to determine the particle size distribution and mass from a pre-metered electro-dose sucked up from the device member **73** through a mouthpiece **78** using an Andersen
5 Impactor **74** to determine the particle size distribution. The total pressure drop over the de-agglomeration set-up is measured with the pressure gauge **75** and the flow-rate of the air is measured with a flowmeter **76** in liters/minute. Suction may be achieved by means of a pumping device **77**.

10 All measurements of the particle size distribution is measured at two different pressure drops over the inhaler device first all measurements are the performed according to USP and only the pressure is changed for the measurement at a lower pressure 1kPa over the inhaler device **71** in point **79**.

15

A complementary particle size distribution is also measured at 1kPa pressure drop over the de-agglomeration #2 set-up **71** indicated by the pressure gauge **79** as diffirential pressure to the atmosphere and then the obtained flow rate is noted down and named Q_{1kPa} . The particle size
20 distribution obtained at the flow rate Q_{1kPa} is the compared with the particle size distribution obtained at the flow rate Q . the flow rate obtained by using all other settings according to the USP, and naming this flowrate Q_{1kPa} and the resulting calculated The result of the test of de-agglomeration #2 at two different pressures over the inhaler device and compared according to fig 16
25 to determine if the result meets the specification for an electro-dose and also if the de-agglomeration for 3 and 5 μm , $DD_{3\mu m, 1kPa}$ and $DD_{5\mu m, 1kPa}$ are within the specifications of the medical drug.

25

30

Thus the method and process according to the present disclosure will result in a very well defined electro-dose for utilization in a dry powder inhaler resulting in a small standard deviation of the doses for repeated administrations.

It will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departure from the scope thereof, which is defined by the appended claims.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175

CLAIMS

Huvudfaxen Kassar

1. An electro-dose constituting a medical powder intended for use in a dry powder inhaler, **characterized in** that the electro-dose is prepared from an electro-powder constituting an active powder substance or a dry powder medical formulation, which is metered onto a device member forming a dose carrier, giving a fine particle fraction (FPF) presenting of the order 50 % or more of its content with a particle size between 0.5-5 μm , the dose further presenting an optimized porosity of 75 to 99.9 %.
2. The electro-dose according to claim 1, **characterized in** that the metered electro-dose constitutes an electro-powder providing electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 $\mu\text{C/g}$ and presents a charge decay rate constant Q_{50} of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity a_w of less than 0.5.
3. The electro-dose according to claim 1, **characterized in** that the metered electro-powder after a mechanical vibration of the dose receiving device member during the metering operation is adjusted to a porosity presenting a value in percent between 75 and 99.9.
4. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, after analysis by a laser triangular method for a total volume calculation and a HPLC or weighing operation for determining the electro-dose mass, the porosity of the electro-dose, calculated in percent as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$, presents a value in percent between 75 and 99.9.
5. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, onto a surface area of the device member forming a dose carrier, has a height less than 800 μm .

2000-08-31

Huvudfaxen Kassan

6. The electro-dose according to claim 1, **characterized in** that the metered electro-dose by using mechanical vibrations of the device member is adjusted to a porosity having in percent a value between 75 and 99.9.

5 7. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, by using a frequency oscillation in the electrical field, is adjusted to a porosity having in percent a value between 75 and 99.9.

8. A method for preparing a metered electro-dose of electro-powder for
10 administration into the deep or upper lung airways by oral inhalation by a dry powder inhaler device, **characterized by** the steps of:

dosing a medical powder, being a preparation of chemical and biological substance forming an electro-powder onto a device member constituting a dose carrier

15 forming of a metered electro-dose bed onto the dose carrier using electrical field technology;

combining the electrical field technology with a mechanical vibration and/or an applied electrical frequency;

20 analyzing the metered electro-dose bed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity;

comparing the analysis result with predefined dosing parameters for deciding that the metered electro-dose at the dose carrier complies with the basic requirements for administration by the inhaler.

25 9. The method according to claim 8, **characterized by** the further step of controlling that the metered electro-dose has an optimized porosity of 75 to 99.9 %.

30 10. The method according to claim 8, **characterized by** the further step of utilizing mechanical vibration of the dose receiving device member during the dosing operation to adjust the metered electro-dose powder porosity to an optimized value in percent between 75 and 99.9.

11. The method according to claim 8, **characterized by** the further step of analyzing the metered electro-dose by a laser triangular method and a HPLC or weighing operation for a total volume calculation to determine the electro-dose mass in order to calculate the electro-dose powder porosity in percent as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ obtaining an optimized value in percent between 75 and 99.

12. The method according to claim 8, **characterized by** the further step of preparing the metered electro-dose onto a surface area of the device member, to obtain an electro-dose height of less than 800 μm .

13. The method according to claim 12, **characterized by** the further step of controlling the metered electro-dose height by means of a triangular laser measuring instrument.

14. The method according to claim 8, **characterized by** the further step of additionally preparing the pre-metered electro-dose by using an oscillating electrical field to adjust the porosity of the electro-dose to an optimized value in percent of 75 to 99.9.

15. The method according to claim 8, **characterized by** the further step of preparing the electro-dose using at least one active electrical filter with a control potential switched on and off within a voltage range $V_{\text{low electrical field}} \leq V_{\text{filter}} \leq V_{\text{device member}}$ during the metering process and using an opening area per controlled opening of the active electrical filter in a range of $0.02 \leq \text{Filter opening} \leq 75 \text{ mm}^2$.

16. The method according to claim 8, **characterized by** the further step of measuring metered electro-dose mass by draining the electrostatic charge into a electrometer determining the specific charge in $\mu\text{C} / g_{\text{electro-powder}}$.

17 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a contrast analyzing method and controlling height of the electro-dose to be less than 800 μm .

5 18 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a laser triangulation method and controlling height of the electro-dose to be less than 800 μm .

10 19 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a image analyzing method and controlling height of the electro-dose to be less than 800 μm .

15 20 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a combination of image analysis, laser triangulation, contrast methods to ensure a height of the electro-dose to be less than 800 μm .

20 21 The method according to claim 8, **characterized by** the further step of measuring electro-dose deagglomeration using a Andersen Impactor for aerodynamic particle size distribution or a Malvern Mastersizer S to determine the physical particle size distribution for a calculation and optimization of the deagglomeration of the electro-dose by changing the porosity.

25 22. A process of preparing doses of powder to be used for administration by a dry powder inhaler, **characterized in that**

a medical powder, being a preparation of a chemical and/or biological substance forming an electro-powder, is metered onto a device member constituting a dose carrier thereby forming a metered electro-dose;

30 a metered electro-dose bed is formed on the dose carrier material using electrical field technology;

the obtained metered electro-dose bed is analyzed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity; and

5 a result of the analysis is compared with predefined dosing parameters for deciding that the prepared metered electro-dose of powder on the dose carrier complies with the basic requirements for administration by the inhaler.

10 23. The process according to claim 22, **characterized in** that electrical field technology is combined with a mechanical vibration and/or an applied electrical frequency.

15 24. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by ionized air to remove electrostatic charges from its surface.

20 25. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by introducing the device member into humid air to remove electrostatic charge from its surface.

25 26. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by combination of ionized air and humid air to remove electrostatic charges from its surface.

30 27. The process according to claim 22, **characterized in** that electro-conductive material is mixed into a plastic material constituting the device member.

28. The process according to claim 22, **characterized in** that electro-conductive material is coated onto a plastic material constituting the device member.

29. The process according to claim 27 or 28, **characterized in that** the conductive material and the plastic material combination of the device member has a specification presenting a surface resistance of $10^3 - 10^{12} \Omega$, and a volume resistivity of $10^3 - 10^{12} \text{ ohm}\cdot\text{m}$.

5

30. The process according to claim 22, **characterized in that** electro-conductive material used for the device member is obtained from any of materials such as silver powder, platinum powder, gold powder, stainless steel powder, antimony-doped tin oxide, antimony-doped silica oxide, or is a
10 X-doped silica where X is an adamantine semiconductor, e.g., Ge, ZnO, GaSb or an octahedral semiconductor, e.g. SnSe, AgSbSe₂, InSb or carbon or any other electro-conductive material approved by FDA and possible to incorporate into plastics.

15 31. The process according to claim 22, **characterized in that** the device member is temporarily given a dissipative surface by applying a thin solvent layer onto the surface e.g. water, carbon dioxide or other non-toxic and FDA approved solvent with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing and
20 metering removing the solvent from the device member.



ABSTRACT

An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a metered medical powder and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being transferred onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presents a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5-5 μm . The electro-powder of such a metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 $\mu\text{C/g}$ and presents a charge decay rate constant Q_{50} of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity a_w of less than 0.5.

The electro-dose porosity is adjusted by means of mechanical and/or electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value in percent of 75 to 99.9 calculated as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$. The method and the processing of electro-doses is partly illustrated by a flow-chart in which steps 220 to 270 present parameters necessary to be kept under strict control.

(Fig. 2)



Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassar

1/13




Fig. 1

Ink t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassar




Fig. 2

3/13

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfoxen Kassar




Fig. 3

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassan

4/13




Fig. 4




Fig. 5

Ink. t. Patent- och reg.verket

2000 -08- 3 1

5/13




Fig. 6




Fig. 7




Fig. 8

7/13




Fig. 9

8/13




Fig.10

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassa

9/13




Fig. 11




Fig. 12

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassan

10/13




Fig. 13




Fig. 14

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfoxen Kassar

11/13




Fig. 15




Fig. 16

Ink. t. Patent- och reg.verket

2000 -08- 3 1

Huvudfoxen Kossan




Fig. 17




Fig. 18

Ink. t. Patent- och reg.verket

2000-08-31

Huvudfaxen Kassar

13/13




Fig. 19